Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 7
2015 5
2016 6
2017 4
2018 4
2019 7
2020 9
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Comparaison du rapport coût-efficacité de la toxine botulinique de type A associé aux meilleurs soins de support vs les meilleurs soins de support seuls dans le traitement de l'hyperactivité vésicale idiopathique avec incontinence urinaire chez les patients réfractaires au traitement anti-cholinergique en France.
Turner L, Velard ME, Loveman C, Khalaf K, Roze S, Pignata M, Stanisic S, Lister J, Ruffion A. Turner L, et al. Prog Urol. 2014 Nov;24(13):799-800. doi: 10.1016/j.purol.2014.08.040. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461566 French. No abstract available.
Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France.
Bregman B, Teitsson S, Orsini I, Cotté FE, Amadi A, Moshyk A, Roze S, Gaudin AF. Bregman B, et al. Dermatol Ther (Heidelb). 2020 Dec;10(6):1331-1343. doi: 10.1007/s13555-020-00446-z. Epub 2020 Sep 13. Dermatol Ther (Heidelb). 2020. PMID: 32920709 Free PMC article.
Health state utilities and adverse events disutilities were derived from the CheckMate 238 trial and literature. Costs were estimated in 2019 euros. The model's primary outcome was efficiency frontier. Deterministic and probabilistic sensitivity analyses were conducted to …
Health state utilities and adverse events disutilities were derived from the CheckMate 238 trial and literature. Costs were estimated in 201 …
43 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page